+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Locoregional recurrence of HER2-positive breast cancer - treatment after complete remission and long-term clinical benefits



Locoregional recurrence of HER2-positive breast cancer - treatment after complete remission and long-term clinical benefits



Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(12): 1924-1926



We report 7 cases of locoregional recurrence in human epidermal growth factor receptor 2 (HER2)-positive breast cancer that we treated. An early complete response (CR) and long-term response was achieved in 5 cases. There were 4 HER2- subtype and 3 Luminal HER2-type cases. Metastasis and recurrence were detected in the residual breast tissue and the supraclavicular, axillary, and parasternal lymph nodes. Chemotherapy consisting of trastuzumab was administered as first-line treatment. A CR was observed 3-4 months after the initiation of therapy in 4 cases, and the time to progression was 27.6- 65.8 months. After achieving a CR, 3 patients terminated treatment and 2 patients continued to take trastuzumab. However, due to adverse effects associated with the chemotherapy, 1 patient changed to endocrine therapy. A second, long-term, CR was achieved in 2 relapsed CR patients by re-challenging with the same chemotherapy regimen. Two patients did not achieve CR and died due to distant metastases. For a better quality of life, it is advisable to continue treatment after a clinical CR for solitary or more complex locoregional recurrences. Following the first-line therapy and a so-called chemoholiday, the patient's disease can be re-challenged using the previously sensitive regimen with careful observation.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 058229053

Download citation: RISBibTeXText

PMID: 25731377


Related references

Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report. Oncology Letters 14(2): 1725-1730, 2017

Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registry. Bmc Cancer 14: 806, 2015

Locoregional recurrence in patients with HER2 positive breast cancer. Breast 22(5): 856-862, 2014

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer. Bmc Cancer 18(1): 295, 2018

Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term. Breast Cancer Research 14(2): 308, 2013

Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy. International Journal of Radiation Oncology, Biology, Physics 80(4): 1095-1101, 2011

Locoregional recurrence and metastasis in the long-term follow-up of postmastectomy breast cancer patients with T1T2 tumours and one to three positive lymph nodes. Clinical and Translational Oncology 6(6): 341-346, 2004

Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab. Radiology and Oncology 48(2): 184-188, 2014

Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature. Targeted Oncology 10(2): 297-301, 2016

Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment. Plos One 13(6): E0198141, 2018

Complete response and long-term remission to anti-HER2 combined therapy in a patient with breast cancer presented with bone marrow metastases. Journal of Oncology Pharmacy Practice 20(2): 141-145, 2014

Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer. Annals of Surgical Oncology 21(11): 3490-3496, 2015

Comparison of locoregional recurrence in triple-negative and HER2-positive breast cancer subtype after breast-conserving therapy and modern systemic therapy. Journal of Clinical Oncology 29(27_suppl): 112-112, 2016

Adjuvant Trastuzumab Reduces Locoregional Recurrence in Women Who Receive Mastectomy for Early-stage, Her2-Positive Breast Cancer Without Radiation Therapy. International Journal of Radiation Oncology*biology*physics 96(2): E24-E25, 2016

Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. JAMA Oncology 2(6): 751-760, 2017